logo
ResearchBunny Logo
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

Medicine and Health

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

D. Li, M. Xu, et al.

This study by Dateng Li and colleagues investigates how the combination of casirivimab and imdevimab (CAS + IMD) remarkably speeds up the resolution of COVID-19 symptoms in high-risk outpatients. With significant benefits observed in reducing hospitalization and mortality, particularly for critical symptoms like cough and fever, the research opens new avenues for improving COVID-19 outcomes.

00:00
00:00
Playback language: English
Abstract
This study investigated the impact of casirivimab and imdevimab (CAS + IMD) treatment on COVID-19 symptom resolution in high-risk outpatients. The analysis revealed that CAS + IMD significantly accelerated the resolution of 17 out of 23 symptoms compared to placebo, particularly in patients lacking robust early antibody responses. Resolution of five key symptoms (dyspnea, cough, fever, fatigue, loss of appetite) independently correlated with reduced hospitalization and death. Treatment benefits were observed across various risk profiles and even in those with late seroconversion. These findings highlight the potential of CAS + IMD to improve COVID-19 outcomes by accelerating symptom resolution.
Publisher
Scientific Reports
Published On
Aug 23, 2023
Authors
Dateng Li, Meng Xu, Andrea T Hooper, Diana Rofail, Kusha A Mohammadi, Yiziying Chen, Shazia Ali, Thomas Norton, David M Weinreich, Bret J Musser, Jennifer D Hamilton, Gregory P Geba
Tags
casirivimab
imdevimab
COVID-19
symptom resolution
high-risk outpatients
hospitalization
seroconversion
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny